Psychiatry & Neurology Doctors in Fort Gratiot, MI Accepting Medicare

6 Psychiatry & Neurology doctors found. Showing 1 - 6

Mr. Richard R Kovar, DO Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 3825 24th Ave, Fort Gratiot, MI 48059 Phone: 810-982-0100    Fax: 810-982-0365

Dr. Omar A Turk, Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 4190 24th Ave, Suite 210, Fort Gratiot, MI 48059 Phone: 810-216-1901    Fax: 810-216-1701

Nalini Samuel, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 3050 Krafft Rd, Fort Gratiot, MI 48059 Phone: 810-385-7700    Fax: 810-385-7760

Lawrence Joseph Zimmer, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1501 Krafft Rd, Fort Gratiot, MI 48059 Phone: 810-985-5125    Fax: 810-985-5127

Dr. Mario Roberto Lanni, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1501 Krafft Rd, Fort Gratiot, MI 48059 Phone: 810-985-5125    Fax: 810-985-5127

Devprakash Samuel, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 3050 Krafft Rd, Fort Gratiot, MI 48059 Phone: 810-385-7700    Fax: 810-385-7760

News Archive

American Anesthesiology acquires BAA

American Anesthesiology, a division of MEDNAX, Inc., today announced the acquisition of Brazos Anesthesiology Associates, P.A. (BAA), a physician group practice based in Bryan, Texas that provides anesthesia services, including cardiac, pediatric, obstetric, regional anesthesia and chronic pain management, throughout the Brazos Valley.

Calgary researchers discover new class of anti-inflammatory agents

By using a mouse model of inflammation researchers at the University of Calgary have discovered a new class of molecules that can inhibit the recruitment of some white blood cells to sites of inflammation in the body.

Tokai Pharmaceuticals raises $35.5M in Series E financing

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.

International 'A' team unveils new glioblastoma atlas

It takes an "A" team to make headway against glioblastoma, a highly aggressive type of brain cancer. Glioblastoma is the most common type of malignant brain tumor in adults. In addition to the caliber of the researchers involved, in this case "A" also stands for atlas.

Read more Medical News

› Verified 3 days ago